Sanofi-Synthelabo Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Paris France (1999)
Status: Acquired by Sanofi-Aventis (2004)

Organization Overview

First Clinical Trial
1999
NCT00224679
First Marketed Drug
1999
doxercalciferol (hectorol)
First NDA Approval
2001
fondaparinux sodium (arixtra)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sanofi-Synthelabo | SANOFI SYNTHELABO